MedTrace Logo

Combination Chemotherapy in Treating Young Male Patients With Hodgkin's Lymphoma

NCT00398554 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2020-03-26

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving combination chemotherapy may kill more cancer cells.

PURPOSE: This phase II trial is studying the side effects and how well combination chemotherapy works in treating young male patients with Hodgkin's lymphoma.

Conditions

Interventions

DRUG

cyclophosphamide

1250 mg/m2 i.v. 60 Min.-Inf. day 1 and 21

DRUG

doxorubicin hydrochloride

25mg/m²/day, 2 hours i.v.infusion on day 21

DRUG

etoposide

150 mg/m²/day, 2 hours i.v.infusion (intravenous drip) on days 1 - 3

DRUG

prednisone

40 mg/m2/day p.o. (intake by mouth)divided in 3 single doses daily from day 1 - 14 and day 21 - 34

DRUG

vinblastine sulfate

6 mg/m² i.v. bolus on day 1 and day 21

DRUG

vincristine sulfate

1,5 mg/m2 i.v. bolus max. single dose 2 mg (cap dose at 2 mg) on day 8 and day 29

RADIATION

radiation therapy

involved field irradiation, single daily fractions 1,5 Gy to max. 1,8 Gy standard dose 20 Gy, max dose 30 Gy (boost irradiation if required)

Sponsors & Collaborators

  • Martin-Luther-Universität Halle-Wittenberg

    collaborator OTHER

  • Christine Mauz-Körholz

    lead OTHER

Principal Investigators

  • Dieter Koerholz, MD · Martin-Luther-Universität Halle-Wittenberg

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-06-30
Primary Completion
2012-10-31
Completion
2013-03-31

Countries

  • Germany
  • Switzerland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00398554 on ClinicalTrials.gov